FDA schedules panel review of Sanofi's Multaq in March

11/30/2008 | Bloomberg · Reuters

Sanofi-Aventis announced that an FDA advisory committee will meet March 18 to evaluate Multaq, a drug candidate for atrial fibrillation. The move delays the agency's decision on the medicine, which secured priority-review status in July. Multaq could generate more than $2 billion in yearly sales, some analysts said.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX